Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors

Journal of Therapeutic Ultrasound

Joo Ha Hwang¹  Hong Chen¹ 

[1] Division of Gastroenterology, Department of Medicine, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA

关键词: Targeted drug delivery;    Cancer;    Ultrasound-targeted microbubble destruction;    Ultrasound contrast agent;    Microbubbles;    Ultrasound;   

Others  :  802915
DOI  :  10.1186/2050-5736-1-10

 received in 2013-01-29, accepted in 2013-04-02,  发布年份 2013

【 摘 要 】

Ultrasound-targeted microbubble destruction (UTMD) is a promising technique for non-invasive, targeted drug delivery, and its applications in chemotherapeutic drug delivery to solid tumors have attracted growing interest. Ultrasound, which has been conventionally used for diagnostic imaging, has evolved as a promising tool for therapeutic applications mainly because of its ability to be focused deep inside the human body, providing a modality for targeted delivery. Although originally being introduced into clinics as ultrasound contrast agents, microbubbles (MBs) have been developed as a diagnostic and therapeutic agent that can both be tracked through non-invasive imaging and deliver therapeutic agents selectively at ultrasound-targeted locations. Whereas free drugs often possess harmful side effects, their encapsulation in MBs and subsequent local release at the targeted tissue by ultrasound triggering may help improve the margin of safety. In the past 10 years, the feasibility and safety of UTMD have been extensively tested using normal animal models. Most recently, a growing number of preclinical studies have been reported on the therapeutic benefits of UTMD in the delivery of chemotherapeutic drugs to various malignant tumors, such as brain, liver, eyelid, pancreas, and breast tumors. Increased drug concentration in tumors and reduced tumor sizes were achieved in those tumors treated with UTMD in combination with chemotherapeutic drugs, when compared to tumors treated with chemotherapy drugs alone. This review presents an overview of current preclinical applications of UTMD in chemotherapeutic drug delivery for the treatment of cancers along with a discussion of its future developments.

【 授权许可】

   
2013 Chen and Hwang; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer. 2006, 6:583-92.
• [2]Reddy LH: Drug delivery to tumours: recent strategies. J Pharm Pharmacol. 2005, 57:1231-42.
• [3]Tredan O, Galmarini CM, Patel K, Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007, 99:1441-54.
• [4]Deckers R, Moonen CTW: Ultrasound triggered, image guided, local drug delivery. J Control Release. 2010, 148:25-33.
• [5]Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T: Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med. 2012, 53:345-8.
• [6]Stride EP, Coussios CC: Cavitation and contrast: the use of bubbles in ultrasound imaging and therapy. Proc Inst Mech Eng H. 2010, 224:171-91.
• [7]Miller DL, Smith NB, Bailey MR, Czarnota GJ, Hynynen K, Makin IR: Overview of therapeutic ultrasound applications and safety considerations. J Ultrasound Med. 2012, 31:623-34.
• [8]Mason TJ: Therapeutic ultrasound an overview. Ultrason Sonochem. 2011, 18:847-52.
• [9]Pitt WG, Husseini GA, Staples BJ: Ultrasonic drug delivery – a general review. Expert Opin Drug Del. 2004, 1:37-56.
• [10]Stride E, Saffari N: Microbubble ultrasound contrast agents: a review. Proc Inst Mech Eng H. 2003, 217:429-47.
• [11]Mayer CR, Geis NA, Katus HA, Bekeredjian R: Ultrasound targeted microbubble destruction for drug and gene delivery. Expert Opin Drug Deliv. 2008, 5:1121-38.
• [12]Bekeredjian R, Kroll RD, Fein E, Tinkov S, Coester C, Winter G, Katus HA, Kulaksiz H: Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med Biol. 2007, 33:1592-8.
• [13]Geis NA, Katus HA, Bekeredjian R: Microbubbles as a vehicle for gene and drug delivery: current clinical implications and future perspectives. Curr Pharm Des. 2012, 18:2166-83.
• [14]Evans KD, Weiss B, Knopp M: High-intensity focused ultrasound (HIFU) for specific therapeutic treatments: a literature review. J Diagn Med Sonog. 2007, 23:319-27.
• [15]Coussios CC, Farny CH, Haar GT, Roy RA: Role of acoustic cavitation in the delivery and monitoring of cancer treatment by high-intensity focused ultrasound (HIFU). Int J Hyperthermia. 2007, 23:105-20.
• [16]Ibsen S, Benchimol M, Simberg D, Esener S: Ultrasound mediated localized drug delivery. Adv Exp Med Biol. 2012, 733:145-53.
• [17]Hernot S, Klibanov AL: Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Del Rev. 2008, 60:1153-66.
• [18]Ferrara K, Pollard R, Borden M: Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng. 2007, 9:415-47.
• [19]Mitragotri S: Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov. 2005, 4:255-60.
• [20]Tsutsui JM, Xie F, Porter RT: The use of microbubbles to target drug delivery. Cardiovasc Ultrasound. 2004, 2:23. BioMed Central Full Text
• [21]Pua EC, Pei Z: Ultrasound-mediated drug delivery. IEEE Eng Med Biol Mag. 2009, 28:64-75.
• [22]Wong KK, Huang I, Kim YR, Tang H, Yang ES, Kwong KK, Wu EX: In vivo study of microbubbles as an MR susceptibility contrast agent. Magn Reson Med. 2004, 52:445-52.
• [23]Sonoda S, Tachibana K, Uchino E, Yamashita T, Sakoda K, Sonoda KH, Hisatomi T, Izumi Y, Sakamoto T: Inhibition of melanoma by ultrasound-microbubble-aided drug delivery suggests membrane permeabilization. Cancer Biol Ther. 2007, 6:1276-83.
• [24]Watanabe Y, Aoi A, Horie S, Tomita N, Mori S, Morikawa H, Matsumura Y, Vassaux G, Kodama T: Low-intensity ultrasound and microbubbles enhance the antitumor effect of cisplatin. Cancer Sci. 2008, 99:2525-31.
• [25]Arvanitis CD, Livingstone MS, Vykhodtseva N, McDannold N: Controlled ultrasound-induced blood–brain barrier disruption using passive acoustic emissions monitoring. PLoS One. 2012, 7:e45783.
• [26]Liu HL, Hua MY, Yang HW, Huang CY, Chu PC, Wu JS, Tseng IC, Wang JJ, Yen TC, Chen PY, Wei KC: Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci USA 2010, 107:15205-10.
• [27]Stride E, Saffari N: Microbubble ultrasound contrast agents: a review. Proc Inst Mech Eng Pt H J Eng Med. 2003, 217:429-47.
• [28]Li P, Zheng Y, Ran H, Tan J, Lin Y, Zhang Q, Ren J, Wang Z: Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice. J Control Release. 2012, 162:349-54.
• [29]Kang J, Wu X, Wang Z, Ran H, Xu C, Wu J, Zhang Y: Antitumor effect of docetaxel-loaded lipid microbubbles combined with ultrasound-targeted microbubble activation on VX2 rabbit liver tumors. J Ultrasound Med. 2010, 29:61-70.
• [30]Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA: Noninvasive MR imaging-guided focal opening of the blood–brain barrier in rabbits. Radiology. 2001, 220:640-46.
• [31]Choi JJ, Selert K, Vlachos F, Wong A, Konofagou EE: Noninvasive and localized neuronal delivery using short ultrasonic pulses and microbubbles. Proc Natl Acad Sci USA 2011, 108:16539-44.
• [32]Konofagou EE, Tung YS, Choi J, Deffieux T, Baseri B, Vlachos F: Ultrasound-induced blood–brain barrier opening. Curr Pharm Biotechnol. 2012, 13:1332-45.
• [33]Deng CX: Targeted drug delivery across the blood–brain barrier using ultrasound technique. Ther Deliv. 2010, 1:819-48.
• [34]Liu HL, Hua MY, Chen PY, Chu PC, Pan CH, Yang HW, Huang CY, Wang JJ, Yen TC, Wei KC: Blood–brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology. 2010, 255:415-25.
• [35]Ting CY, Fan CH, Liu HL, Huang CY, Hsieh HY, Yen TC, Wei KC, Yeh CK: Concurrent blood–brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials. 2012, 33:704-12.
• [36]Treat LH, McDannold N, Zhang Y, Vykhodtseva N, Hynynen K: Improved anti-tumor effect of liposomal doxorubicin after targeted blood–brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med Biol. 2012, 38:1716-25.
• [37]Cochran MC, Eisenbrey JR, Soulen MC, Schultz SM, Ouma RO, White SB, Furth EE, Wheatley MA: Disposition of ultrasound sensitive polymeric drug carrier in a rat hepatocellular carcinoma model. Acad Radiol. 2011, 18:1341-8.
• [38]Tinkov S, Coester C, Serba S, Geis NA, Katus HA, Winter G, Bekeredjian R: New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: in-vivo characterization. J Control Release. 2010, 148:368-72.
• [39]Sorace AG, Warram JM, Umphrey H, Hoyt K: Microbubble-mediated ultrasonic techniques for improved chemotherapeutic delivery in cancer. J Drug Target. 2012, 20:43-54.
• [40]Miller MW, Brayman AA: Biological effects of ultrasound The perceived safety of diagnostic ultrasound within the context of ultrasound biophysics: a personal perspective. Echocardiography. 1997, 14:615-28.
• [41]Streeter JE, Gessner R, Miles I, Dayton PA: Improving sensitivity in ultrasound molecular imaging by tailoring contrast agent size distribution: in vivo studies. Mol Imaging. 2010, 9:87-95.
• [42]Choi JJ, Feshitan JA, Baseri B, Wang S, Tung YS, Borden MA, Konofagou EE: Microbubble-size dependence of focused ultrasound-induced blood–brain barrier opening in mice in vivo. IEEE Trans Biomed Eng. 2010, 57:145-54.
• [43]Paliwal S, Mitragotri S: Ultrasound-induced cavitation: applications in drug and gene delivery. Expert Opin Drug Deliv. 2006, 3:713-26.
• [44]Tu J, Hwang JH, Matula TJ, Brayman AA, Crum LA: Intravascular inertial cavitation activity detection and quantification in vivo with Optison. Ultrasound Med Biol. 2006, 32:1601-9.
• [45]Tung YS, Vlachos F, Choi JJ, Deffieux T, Selert K, Konofagou EE: In vivo transcranial cavitation threshold detection during ultrasound-induced blood–brain barrier opening in mice. Phys Med Biol. 2010, 55:6141-55.
• [46]Jensen CR, Ritchie RW, Gyongy M, Collin JR, Leslie T, Coussios CC: Spatiotemporal monitoring of high-intensity focused ultrasound therapy with passive acoustic mapping. Radiology. 2012, 262:252-61.
• [47]O’Reilly MA, Hynynen K: Blood–brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology. 2012, 263:96-106.
• [48]Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Ruckert F, Grutzmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M, et al.: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009, 324:1457-61.
• [49]Tung YS, Marquet F, Teichert T, Ferrera V, Konofagou EE: Feasibility of noninvasive cavitation-guided blood–brain barrier opening using focused ultrasound and microbubbles in nonhuman primates. Appl Phys Lett. 2011, 98:163704.
• [50]McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS: Temporary disruption of the blood–brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012, 72:3652-63.
• [51]Miller DL, Averkiou MA, Brayman AA, Everbach EC, Holland CK, Wible JH, Wu JR: Bioeffects considerations for diagnostic ultrasound contrast agents. J Ultrasound Med. 2008, 27:611-32.
• [52]ter Haar G: Safety and bio-effects of ultrasound contrast agents. Med Biol Eng Comput. 2009, 47:893-900.